Device Trial Radar · NCT03066700
Prognostic Factors in Malignant GI Bleeding Treated With Hemostatic Powder
Last checked: Nov 19, 2026Latest source record: Feb 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Mar 1, 2017
Primary completion
Jun 1, 2017
Study completion Aug 31, 2017
Sponsor
- Lead sponsor
- King Chulalongkorn Memorial HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- McGill University
- First posted
- Feb 28, 2017
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a retrospective study to identify the prognostic factors of the good outcomes in patients who presented with upper GI bleeding from tumor and received Hemospray via endoscopy for hemostatic control. The good outcomes were assessed by immediate hemostasis, rebleeding at 72 hours as well as 7, 14 and 30 days following presentation at initial bleeding episode and also 6-month survival rate.
Conditions
- Death
Interventions
Hemostatic powderDevice
HemosprayTM (Tc-325) is an endoscopic hemostatis powder that came onto market recently. It is made of an inorganic, non-absorbable powder which acts locally at the mucosa. When spraying the powder on to the bleeding site, it creates an adherent stable barrier sheath that allows for at least temporary hemostasis. Neither luminal nor systemic side effects have been reported to date.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mortality rateTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
King chulalongkorn memorial hospita
Bangkok, Pathum Wan, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.